CANF
No price yet
Announcements
Nothing here yet
Daily updates
FDA designations
Nothing here yet
News
- Can-Fite reported longer-than-expected overall survival in its ongoing pivotal Phase 3 liver cancer studySep 7, 2026
- Can-Fite reported that namodenoson enhanced the anti-cancer effect of chemotherapy in pancreatic cancerAug 17, 2026
- Can-Fite highlighted the advanced FDA and EMA regulatory status of its Phase 3 drug candidatesAug 12, 2026
- Can-Fite launched the first clinical program of piclidenoson for the rare genetic disorder Lowe syndromeAug 3, 2026
- Can-Fite reached a key Phase 3 milestone by completing patient enrollment for the interim psoriasis analysisJul 8, 2026